Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Decided to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using miRNA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Acquired a 50% Stake in Ros Vivo Therapeutics, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RosVivo Therapeutics, Inc. Signed a Material Transfer Agreement (MTA) for First-In-Class Diabetes Treatment With Eli Lilly and Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by RosVivo Therapeutics

    Menu

    RosVivo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RosVivo Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RosVivo Therapeutics, Inc. Signed a Material Transfer Agreement (MTA) for First-In-Class Diabetes Treatment With Eli Lilly and Company

              Details:

              RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate that can fundamentally treat diabetes by restoring the function of beta cells that secrete insulin, the cause of diabetes, and at the same time lowering insulin resistance.

              Lead Product(s): RSVI-301

              Therapeutic Area: Endocrinology Product Name: RSVI-301

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RosVivo Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nexturn Bio Inc. Acquired a 50% Stake in Ros Vivo Therapeutics, Inc.

              Details:

              RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency, showed a prolonged effect, and alleviated side effects such as GI dysmotility in animal studies. It is expected that RSVI-301 will become a first-in-class diabetic drug.

              Lead Product(s): miRNA Based Therapy

              Therapeutic Area: Endocrinology Product Name: RSVI-301

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Nexturn Bio

              Deal Size: $5.5 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RosVivo Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nexturn Bio Inc. Decided to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using miRNA

              Details:

              RosVivo recently developed RSVI-301, a new drug pipeline that utilizes miRNA, which is expected to be the next-generation drug, following mRNA, which has attracted attention as a Covid-19 vaccine.

              Lead Product(s): miRNA based therapy

              Therapeutic Area: Endocrinology Product Name: RSVI-301

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Nexturn Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition May 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY